Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources

Wang, Wei; Kothari, Smita; Baay, Marc; Garland, Suzanne M.; Giuliano, Anna R.; Nygård, Mari; Velicer, Christine; Tota, Joseph E.; Sinha, Anushua; Skufca, Jozica; Verstraeten, Thomas; Sundström, Karin

doi:10.1080/14760584.2022.2008243

Cited by 8 publications

(7 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among general population women, the prevalence of hrHPV in Estonia and Lithuania is higher than that reported from central and western European countries and is comparable to former Soviet Union countries [18,20,25,36,37]. This tendency might be explained by the influence of the primary prevention (insufficient sexual education at schools as well as the limited effect of HPV vaccination -it has been introduced in 2018 in Estonia for girls aged 12-14 years (12 years since 2020) and in 2016 in Lithuania for girls aged 11 years, but the coverage seems to be insufficient (31.3% in Estonia in 2019, no data for Lithuania), cultural and regional relations from Soviet Union times but also can be attributed to the differences in study design and use of different HPV testing methods [38].…”

Section: Disease Burdenmentioning

confidence: 99%

An overview of cervical cancer epidemiology and prevention in the Baltic States

et al. 2023

View full text Add to dashboard Cite

Aims To inform future Baltic States-specific policy analyses, we aimed to provide an overview of cervical cancer epidemiology and existing prevention efforts in Estonia, Latvia and Lithuania. Methods A structured desk review: we compiled and summarized data on current prevention strategies, population demography and epidemiology (high risk human papillomavirus (HPV) prevalence and cervical cancer incidence and mortality over time) for each Baltic State by reviewing published literature and official guidelines, performing registry-based analyses using secondary data and having discussions with experts in each country. Results We observed important similarities in the three Baltic States: high burden of the disease (high incidence and mortality of cervical cancer, changes in TNM (Classification of Malignant Tumors) stage distribution towards later stage at diagnosis), high burden of high-risk HPV in general population and suboptimal implementation of the preventive strategies as low screening and HPV vaccination coverage. Conclusions Cervical cancer remains a substantial health problem in the region and the efforts in addressing barriers by implementing a four-step plan for elimination cervical cancer in Europe should be made. This goal is achievable through evidence-based steps in four key areas: vaccination, screening, treatment, and public awareness.

show abstract

Section: Disease Burdenmentioning

confidence: 99%

An overview of cervical cancer epidemiology and prevention in the Baltic States

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The prophylactic effectiveness and safety of the HPV vaccine are clearly established in both men and women [ 38 , 39 , 40 , 41 , 42 ]. This was also demonstrated by a retrospective analysis involving 942,841 women aged 9–28.…”

Section: Discussionmentioning

confidence: 99%

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Șandru,

Radu,

Petca

et al. 2024

Vaccines

View full text Add to dashboard Cite

Human papillomavirus (HPV) encompasses a diverse array of viruses, comprising approximately 200 serotypes that affect humans. While the majority of HPV strains are associated with benign skin or mucous membrane growths, a subset is implicated in severe health conditions, such as cervical, anal, vulvar, and vaginal cancers. Despite the established effectiveness of HPV vaccines in preventing cervical and anal carcinomas in particular, their therapeutic potential in addressing cutaneous diseases linked to diverse HPV strains remains an intriguing area of investigation. This narrative review critically examines the existing literature to assess the viability of HPV immunization as a therapeutic intervention for prevalent cutaneous conditions. These include genital and extragenital cutaneous warts, epidermodysplasia verruciformis, and keratinocyte carcinomas. The findings suggest a promising dual role for HPV vaccines in preventing and treating dermatologic conditions while emphasizing future research directions, including the immunization perspective against β-HPVs. Moreover, the presence of conflicting study outcomes underscores the imperative for larger-scale, randomized trials with well-matched control groups to validate the efficacy of HPV immunization in the dermatologic context. This review contributes valuable insights into the evolving landscape of HPV-vaccine applications in the field of dermatology.

show abstract

“…The most common genotypes in the male population are HPV-6, 11, 16, and 18 [ 2 ]. Benign lesions such as external anogenital warts and recurrent respiratory papillomatosis are caused mostly by low-risk types such as HPV-6 and HPV-11 [ 4 , 5 ]. Malignant anogenital and head and neck diseases are more associated with high-risk (HR)-HPV types, of which HPV-16 and HPV-18 are the most common [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Human papillomavirus (HPV)-related diseases are highly prevalent in men worldwide, comprising external anogenital condyloma, anal intraepithelial neoplasia (AIN), penile intraepithelial neoplasia (PIN), and anogenital and oropharyngeal cancers. There is exceptionally low vaccine coverage in the male population. Only 4% of men were fully vaccinated, worldwide, as of 2019. The aim of this review is to assess the impact of HPV vaccination on male disease. Three databases (MEDLINE, Web of Science, Scopus) and Clinical Trials.gov were searched. We included thirteen studies, eight randomized controlled trials (RCTs), and five cohorts, comprising a total of 14,239 participants. Regarding anal disease, seven studies reported HPV vaccine efficacy ranging from 91.1% to 93.1% against AIN1, and ranging from 89.6% to 91.7% against AIN2|3 and anal cancer. Five studies showed an efficacy against genital condyloma of 89.9% in HPV-naïve males, varying between 66.7% and 67.2% in intention-to-treat populations. Studies reporting no efficacy have included older participants. These results support vaccination of young men previously infected, beyond HPV-naïve males. The evidence quality was moderate to low for most outcomes, namely genital diseases. RCTs are needed to assess the efficacy of HPV vaccination on male oropharyngeal cancer.

show abstract

Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources

Cited by 8 publications

References 191 publications

An overview of cervical cancer epidemiology and prevention in the Baltic States

An overview of cervical cancer epidemiology and prevention in the Baltic States

Unveiling the Therapeutic Horizon: HPV Vaccines and Their Impact on Cutaneous Diseases—A Comprehensive Review

Impact of Human Papillomavirus Vaccination on Male Disease: A Systematic Review

Contact Info

Product

Resources

About